Mechanistic insights revealed that ELP treatment modulated the tumor immune microenvironment, leading to increased activation of CD4+ and CD8+ T cells, as well as polarization of tumor-associated macrophages towards the M1 phenotype. The gene discussed is NR5A1; the disease is neoplasm.